We have been searching for new therapies for treatment of virus infections. Last year we concluded a clinical study using CMX-001, a lipid-conjugated form of cidofovir, which has excellent oral bioavailability and lacks the kidney toxicity of cidofovir, in patients with severe herpes simplex, cytomegalovirus, and adenovirus infections. We have also been searching for new viruses in persons with unexplained diseases. Last year we studied cohorts of patients with chronic fatigue syndrome and chronic inflammatory diseases of unknown etiology and did not detect evidence of XMRV infection in these patients. We have also been testing other compounds in vitro for their activity against herpesviruses. Ascorbic acid (vitamin C) has previously been shown to kill various cancer cell lines in vitro at levels that can be achieved in the serum of humans with intravenous dosing. This year we found that Epstein-Barr virus (EBV)-positive Burkitt lymphoma cells were more susceptible to killing by ascorbic acid than EBV-negative Burkitt lymphoma cells or EBV-transformed B cells. Ascorbic acid did not induce programmed cell death (apoptosis) in any of the cells tested, but did induce the production of reactive oxygen species and cell death. Previously, we showed that bortezomib, a proteasome inhibitor that is approved for the treatment of multiple myeloma, induces death of EBV-transformed B cells and EBV-positive Burkitt lymphoma cells. We found that ascorbic acid is strongly antagonistic for bortezomib-induced cell death in EBV-transformed B cells and EBV-positive Burkitt lymphoma cells. Finally, ascorbic acid did not prolong survival of severe combined immunodeficiency mice inoculated with EBV-transformed B cells either intraperitoneally or subcutaneously. Thus, while ascorbic acid was highly effective at killing EBV-positive Burkitt lymphoma cells and EBV-transformed B cells in vitro, it antagonized cell killing by bortezomib and was ineffective in an animal model.

Project Start
Project End
Budget Start
Budget End
Support Year
39
Fiscal Year
2013
Total Cost
$490,842
Indirect Cost
City
State
Country
Zip Code
Dropulic, Lesia K; Ali, Mir A; Ombrello, Amanda K et al. (2016) Periodic Illness Associated With Epstein-Barr Virus: A New Diagnosis After a 22-Year Follow-up. Clin Infect Dis 62:1613-4
Liu, XueQiao; Cohen, Jeffrey I (2016) Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. J Virol 90:1129-38
Liu, XueQiao; Cohen, Jeffrey I (2015) The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside. Virology 479-480:568-77
Bayat, Ahmad; Burbelo, Peter D; Browne, Sarah K et al. (2015) Anti-cytokine autoantibodies in postherpetic neuralgia. J Transl Med 13:333
Li, Qingxue; Wilkie, Adrian R; Weller, Melodie et al. (2015) THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection. PLoS Pathog 11:e1004999
Newman, Ruchi M; Lamers, Susanna L; Weiner, Brian et al. (2015) Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol 89:8219-32
Lamers, Susanna L; Newman, Ruchi M; Laeyendecker, Oliver et al. (2015) Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. J Virol 89:8206-18
Cohen, Jeffrey I (2015) Primary Immunodeficiencies Associated with EBV Disease. Curr Top Microbiol Immunol 390:241-65
Schulz, Katharina S; Liu, Xueqiao; Klupp, Barbara G et al. (2014) Pseudorabies virus pUL46 induces activation of ERK1/2 and regulates herpesvirus-induced nuclear envelope breakdown. J Virol 88:6003-11
Bowman, J Jason; Burbelo, Peter D; Gill, Rachel B et al. (2014) A seroprevalence study of primate workers for asymptomatic rhesus cytomegalovirus infection. J Clin Virol 60:411-3

Showing the most recent 10 out of 22 publications